Drug Profile
Research programme: CD26 antigen inhibitors - Zhejiang Betta Pharma
Alternative Names: BP 711001; BP 712001; Dipeptidyl peptidase IV inhibitors - Zhejiang Betta Pharma; DPP-IV inhibitors - Zhejiang Betta PharmaLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Zhejiang Betta Pharma
- Class Antihyperglycaemics
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in China (PO)
- 09 Jul 2009 Preclinical trials in Type-2 diabetes mellitus in China (PO)